Back to Search
Start Over
Advances in Multiple Myeloma and Spine Disease
- Source :
- Clinical Lymphoma and Myeloma. 6:228-233
- Publication Year :
- 2005
- Publisher :
- Elsevier BV, 2005.
-
Abstract
- Progressive bone destruction is the hallmark of multiple myeloma (MM) and is responsible for principal morbidity in the disease. The spine is the most afflicted skeletal organ, and vertebral fractures have significantly contributed to its poor prognosis. The principal underlying pathologic mechanism causing bone disease in MM is a shift in the balance of bone formation and bone resorption toward bone resorption, and eventually total dissociation between the 2 processes occurs in latter stages of the disease. During the past decade bisphosphonates have become an important adjunctive treatment in the management of MM, in which they have shown the ability to reduce bony complications associated with the disease. Advances in minimally invasive surgical techniques, such as percutaneous vertebroplasty and kyphoplasty, offer these patients less-invasive options for the treatment of vertebral collapse and restoration of their normal function. This report reviews recent advances in the understanding of bone disease in MM, the role of bisphosphonates in the prevention of skeletal events, and available data regarding percutaneous vertebroplasty and kyphoplasty.
- Subjects :
- Cancer Research
medicine.medical_specialty
Poor prognosis
Bone disease
medicine.medical_treatment
Disease
Bone resorption
Percutaneous vertebroplasty
Animals
Medicine
Bone Resorption
Multiple myeloma
Bone Density Conservation Agents
Diphosphonates
business.industry
Hematology
General Medicine
Prognosis
medicine.disease
Surgery
Oncology
Adjunctive treatment
Spinal Fractures
Vertebral collapse
Radiology
Multiple Myeloma
business
Subjects
Details
- ISSN :
- 15579190
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Clinical Lymphoma and Myeloma
- Accession number :
- edsair.doi.dedup.....758ba59cfede879b6538410925ac6300
- Full Text :
- https://doi.org/10.3816/clm.2005.n.050